RT
The startup develops a first-in-class small molecule allosteric inhibitor targeting HIPK2 to treat renal fibrosis, a chronic condition that leads to kidney damage. This therapy aims to provide a safe and effective anti-fibrotic solution, addressing the critical unmet medical needs of patients suffering from renal fibrosis.
Updated 2 months ago
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a first-in-class small molecule allosteric inhibitor targeting HIPK2 to treat renal fibrosis, a chronic condition that leads to kidney damage. This therapy aims to provide a safe and effective anti-fibrotic solution, addressing the critical unmet medical needs of patients suffering from renal fibrosis.